Navigation Links
Inovio Pharmaceuticals Universal H1N1 Influenza Vaccine Achieves Protective Immune Responses Comparable to Conventional Vaccine in Phase I Study
Date:4/18/2013

vorable safety profile is consistent with multiple studies in different disease areas in which Inovio DNA vaccines delivered with Inovio electroporation delivery devices have been administered to over several hundred subjects.

About Inovio's Universal Influenza DNA Vaccine Program

Inovio aims to leverage the greater breadth of immune responses achievable using its SynCon® vaccine design to revolutionize the flu vaccine market.

We are advancing the development of a universal seasonal flu vaccine to protect against H1N1, H3N2, and Type B influenza strains, the subtypes comprising today's FDA-approved seasonal vaccines. In addition to the ongoing H1N1 study in elderly subjects (65+ years), for which we reported positive interim data in December, the company is completing immunogenicity testing across multiple strains in animal models of its vaccine constructs for A/H3N2 and Type B influenza.

We are also advancing development initiatives focused on the pandemic influenza subtypes H5N1 and H7N9. Our goal is to access the pandemic stockpiling market, which is dominated by government buyers.

About Inovio Pharmaceuticals, Inc.

Inovio is revolutionizing vaccines to prevent and treat today's cancers and challenging infectious diseases. Its SynCon® vaccines are designed to provide universal protection against known as well as new unmatched strains of pathogens such as influenza. These synthetic vaccines, in combination with Inovio's proprietary electroporation delivery, have been shown in humans to generate best-in-class immune responses with a favorable safety profile. Inovio's clinical programs include phase II studies for cervical dysplasia, leukemia and hepatitis C virus and phase I studies for influenza and HIV. Partners and collaborators include the University of Pennsylva
'/>"/>

SOURCE Inovio Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer
2. Inovio Pharmaceuticals Reports 2012 First Quarter Financial Results
3. Inovio Pharmaceuticals to Present at SPI 2012
4. Inovio Pharmaceuticals Universal Avian Flu Vaccine Generates Protective Antibody Responses Against Six H5N1 Viruses in Phase I Trial
5. Inovio Pharmaceuticals to Present at JMP Investor Conference
6. Inovio Initiates H1N1 Universal Influenza Vaccine Clinical Trial Targeting Over-65 Population, Which Represents 90% of Flu Deaths
7. Inovio Pharmaceuticals Inc. to Webcast, Live, at RetailInvestorConferences.com on August 2nd
8. Inovio Pharmaceuticals Inc. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
9. Inovio Pharmaceuticals Reports 2012 Second Quarter Financial Results
10. Inovio Pharmaceuticals Takes Major Stride Toward Universal Influenza Vaccine
11. Inovio Pharmaceuticals Reports 2012 Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... -- The U.S. Department of Health and Human Services (HHS) ... Case Medical Center Seidman Cancer Center totaling $4.7 million ... care for patients with complex cancer. ... unique model developed at UH to enhance care for ... demonstrated need for high health care utilization.  ...
(Date:7/10/2014)... INC. (NYSE: RMD ) today announced that it ... 30, 2014 results on Thursday, July 31, 2014, after the ... ResMed,s results will be issued after 1:00 p.m. US Pacific ... operating results and future outlook. The earnings call ... and the live webcast of the call can be accessed ...
(Date:7/10/2014)... , July 10, 2014  Valeant Pharmaceuticals International, ... today announced it has completed the sale to Galderma ... Dysport owned or held by Valeant for $1.4 billion ... Nestle S.A, which recently completed its acquisition of Galderma. ... divestiture of our products to a company that is ...
Breaking Medicine Technology:University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 2University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 3University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 4ResMed To Announce Fourth Quarter And Fiscal Year-End 2014 Results 2
... levels following 4 weeks of, treatment with R7128 1500mg and Pegasys(R) plus ... tolerability comparable to ... - Conference Call Scheduled for 4:00PM ET Today -, PRINCETON, N.J., ... of a 4-week Phase 1,clinical trial to evaluate two oral dose levels ...
... Duration of ... Neutropenia- ... Jan. 7 Maxygen, Inc.,(Nasdaq: MAXY ) today announced positive progress in ... the trial include the following:, -- Patients in the initial 10 ...
Cached Medicine Technology:Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C 2Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C 3Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C 4Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C 5Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C 6Maxygen Announces Positive Progress in Phase IIa Clinical Trial of Novel PEG-GCSF 2Maxygen Announces Positive Progress in Phase IIa Clinical Trial of Novel PEG-GCSF 3Maxygen Announces Positive Progress in Phase IIa Clinical Trial of Novel PEG-GCSF 4
(Date:7/11/2014)... July 11, 2014 As reported by ... For Cocaine: Are Genetics To Blame (6/30), Indino Downey ... cocaine and paraphernalia to smoke it with. His father, ... that his son inherited from him may have something ... made the news during the 1980s and 1990s for ...
(Date:7/11/2014)... July 11, 2014 Organic Crop ... being launched into the limelight over the past decade. ... was once considered to be an alternative food eaten ... are now purchasing organic food.” Organic crop farmers have ... vegetables, grains, nuts and herbs over the past five ...
(Date:7/11/2014)... new study challenges the widely held belief that light drinking ... analyzed more than 50 studies that examined drinking habits and ... that those with a form of a gene tied to ... affects how a person,s body breaks down alcohol, resulting in ... variant has been shown to lead to lower drinking over ...
(Date:7/11/2014)... 2014 American Farmer is proud to ... July 15, 2014, at 8:30 am ET. , In ... products, which are designed and formulated for use on ... how these products help the crop realize its maximum ... is grown. , The show also features UniSouth Genetics, ...
(Date:7/11/2014)... WA (PRWEB) July 11, 2014 College ... within one week of injury, but developed recurrent instability ... at the American Orthopaedic Society for Sports Medicine’s ( ... guide team physicians in providing the most optimal treatment ... who suffered an anterior shoulder instability event, and found ...
Breaking Medicine News(10 mins):Health News:Roberty Downey's Son Arrested For Cocaine 2Health News:Organic Crop Farming in Australia Industry Market Research Report Now Available from IBISWorld 2Health News:Organic Crop Farming in Australia Industry Market Research Report Now Available from IBISWorld 3Health News:Organic Crop Farming in Australia Industry Market Research Report Now Available from IBISWorld 4Health News:A Little Alcohol May Not Be Good for Your Heart After All 2Health News:New Episode of American Farmer Featuring Sunbelt, UniSouth Genetics, and Michigan Milk Producers Association Airing on RFD-TV 2Health News:Intercollegiate Contact Athletes with Shoulder Instability Return to In-Season Sports, Study Shows 2
... support efforts to reduce air pollution, especially diesel exhaust ... studies from Europe demonstrate the health damage done by ... engines. , An 11-year period of improving air quality ... air in Europe, produced measurable benefits in lung function ...
... healthy lifestyle drives new store openings, PITTSBURGH, Dec. ... new resolution or two. For GNC, it means more ... is expected to rise steadily,through 2012, according to the ... to once again expand its store base and overall,business: ...
... Ky., Dec. 5 Ventas, Inc. (NYSE:,VTR) ... the Executive,Compensation Committee of its Board of ... certain executive officers to encourage their,long-term retention ... to,Raymond J. Lewis, the Company,s Chief Investment ...
... Growing price competition from,low-cost manufacturers has been forcing ... profitable growth, which Kalorama Information predicts,will likely come ... pharmaceutical,medical foods, or biomedical device companies -- a ... Healthcare Opportunities for Food Ingredient,Manufacturers., Thousands of ...
... still debated, experts say , , WEDNESDAY, Dec. 5 (HealthDay News) ... Wednesday that the cancer drug Avastin should not be used ... close vote, 5-4, the advisers decided the drug,s ability to ... increased risk of blood clots and other cardiovascular troubles among ...
... A new white paper,published by The Endocrine ... major new initiatives to ensure effective,broad-based minority participation ... of recommendations to ensure that data from clinical,trials ... The white paper, developed by a special ...
Cached Medicine News:Health News:Cleaner Air Leads to Healthier Lungs 2Health News:Cleaner Air Leads to Healthier Lungs 3Health News:GNC Franchising Expected to Grow Through 2008 2Health News:Ventas Grants Stock Awards to Promote Long-Term Retention and Reward Performance 2Health News:Ventas Grants Stock Awards to Promote Long-Term Retention and Reward Performance 3Health News:Ventas Grants Stock Awards to Promote Long-Term Retention and Reward Performance 4Health News:Medical Industry Offers Food Ingredient Companies More Than One Billion Reasons to Think Healthy 2Health News:FDA Panel Says No to Avastin for Advanced Breast Cancer 2Health News:FDA Panel Says No to Avastin for Advanced Breast Cancer 3Health News:The Endocrine Society Publishes White Paper Calling for Greater Minority Participation in Clinical Research 2Health News:The Endocrine Society Publishes White Paper Calling for Greater Minority Participation in Clinical Research 3Health News:The Endocrine Society Publishes White Paper Calling for Greater Minority Participation in Clinical Research 4
... Plate is a semi-rigid system intended ... The Slim-LOC is based on the ... current market technology. The Slim-LOCTM system ... instrumentation. Reduced width (16 mm), low ...
... SC-Acufix anterior cervical plate system is a ... integrated swivel, which provides for consistent, reliable ... bone screw disengagement or backout. This innovative ... locking screw. Simply implant your screws and ...
... a leading provider of telemedicine solutions. ... state-of-the-art technology deliver accurate, reliable and ... professionals and clients in improving outcomes. ... ECG technology to gather patient data, ...
... is a high performance temperature controlled shaker ... shaking speed and incubation time are fully ... parameters are displayed on the LCD in ... below the microplates provide uniform incubation with ...
Medicine Products: